Skip to main content
. 2017 Mar 17;8(30):49110–49122. doi: 10.18632/oncotarget.16308

Figure 2. Decreased expression of miR-196a-3p correlates with poor clinical outcomes in breast cancer.

Figure 2

The overall survival (OS) (left) and disease-free survival (DFS) (right) curves for the studied patients with high or low miR-196a-3p expression,**p< 0.01.